Videos
-
General Cardio-Oncology Welcome Message from the Program Chair
-
Immune Checkpoint Inhibitors Immune Checkpoint Inhibitors and Cardiotoxicity: The Pharmacist Perspective
-
Immune Checkpoint Inhibitors Immune Checkpoint Inhibitors and Cardiotoxicity: Incidence and Patient Risk Factors
-
Immune Checkpoint Inhibitors Managing Cardiotoxicity Associated With Immune Checkpoint Inhibitor Therapy
-
Kinase Inhibitors Kinase Inhibitors and Cardiotoxicity: The Pharmacist Perpsective
-
Kinase Inhibitors Managing Nilotinib-Associated Cardiotoxicity in CML: A Case Study
-
Kinase Inhibitors Managing Ibrutinib-Associated Cardiotoxicity in CLL: A Case Study
-
HER2-Targeted Therapies HER2-Targeted Therapies and Cardiotoxicity: The Pharmacist Perspective
-
HER2-Targeted Therapies HER2-Targeted Therapies: Cardiotoxicity Incidence
-
HER2-Targeted Therapies Monitoring and Management Strategies for HER2-Targeted Therapy–Associated Cardiotoxicity
-
Novel Immunotherapies Novel Immunotherapies and Cardiotoxicity: The Pharmacist Perspective
-
Novel Immunotherapies Managing Cardiotoxicity Associated With CAR T-Cell Therapy: A Case Study
-
Novel Immunotherapies Managing Cardiotoxicity Associated With BiTE Therapy: A Case Study
